Biostage, Inc. (BSTG) Stock
Biostage, Inc. is a biotechnology enterprise dedicated to developing medical products aimed at curing patients suffering from cancers, injuries, and congenital defects within the gastrointestinal system and respiratory pathways.
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Cash Flow (USD)
Valuation & Return Ratios
Peer Comparison
About Biostage, Inc.
Biostage, Inc. is a biotechnology enterprise dedicated to developing medical products aimed at curing patients suffering from cancers, injuries, and congenital defects within the gastrointestinal system and respiratory pathways. A primary focus for the company is the advancement of its Biostage Esophageal Implant, specifically designed to address esophageal cancer. Founded in 2009, the organization was formerly known as Harvard Apparatus Regenerative Technology, Inc. before rebranding as Biostage, Inc. in March 2016. Its corporate headquarters are located in Holliston, Massachusetts.
Biostage, Inc. is headquartered in US.
Biostage, Inc. (BSTG) stock trades at $4.03 with a market capitalization of $57.82M. The stock is valued at a negative price-to-earnings (P/E) ratio of -9.83, reflecting a net loss over the last twelve months, price-to-book of 770.11, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $3.65 and $9.00, and currently trades 55.2% below its 52-week high.
On profitability, Biostage, Inc. generates a return on equity (ROE) of -786.49% (negative, reflecting a net loss), return on capital employed of -800.00%.
Official website: biostage.com
Related Healthcare Stocks
Popular Stocks
Related stock screens
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.